The Broadband Infrared Diagnostics (BIRD) team is excited to announce that the clinical study “Molecular Fingerprinting for Cancer Detection” has been successfully reactivated and enrolment has started at LMU Hospital just last week! The group’s clinical study team has achieved this significant milestone after months of preparation and planning. Going forward, our study nurses will be actively searching for individuals at the clinic to participate in the study. Using electric-field molecular spectroscopy, our ultimate goal is to develop a medical device to complement current primary cancer diagnostics, which unfortunately still have limitations.
Over the next few years, we plan to enrol thousands of individuals with different types of cancer, as well as control individuals, initially at LMU Hospital of Munich and later at other clinics in Germany. Participating in the study is simple and only requires a small blood donation and filling out a short questionnaire. The BIRD team will process and measure the blood-based samples using infrared spectroscopy at the laser labs of the Ludwig-Maximilians-Universität München (LMU Munich) in Garching.
Reference:
The clinical study is registered and can be viewed at the German Register of Clinical Studies (German Register of Clinical Studies). For more information, please visit our Lasers4Life website website).
